Magnetic Half Generation PAMAM Dendrimeric Nanoparticles for Targeting Delivery of Gemcitabine

2015-06-09
Maryam, Parsian
Mutlu, Pelin
Yalçın Azarkan, Serap
Tezcaner, Ayşen
Gündüz, Ufuk
Antitumor activity of Gemcitabine, a nucleoside analogue, has been reported in a variety of human tumors, including breast cancer in both experimental and clinical studies. Conventional chemotherapeutic agents are unspecifically distributed all over the body where they affect both cancerous and normal cells. They cause major systemic toxicities and drug resistance, which also restricts drugs therapeutic efficacy. Recent advances in nanotechnology have explored new targeting strategies for enhancing intra-tumoral drug concentrations while limiting the systemic toxicity and side effects. Controlled release of Gemcitabine within cancer cells could be achieved by PAMAM coated magnetic nanoparticles (DcMNPs) which could be targeted to the tumor tissue.
Citation Formats
P. Maryam, P. Mutlu, S. Yalçın Azarkan, A. Tezcaner, and U. Gündüz, “Magnetic Half Generation PAMAM Dendrimeric Nanoparticles for Targeting Delivery of Gemcitabine,” presented at the 11th Internatiobal Symposium on Pharmaceutical Sciences, Ankara, Türkiye, 2015, Accessed: 00, 2021. [Online]. Available: https://hdl.handle.net/11511/78879.